Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) EBITDA (2016 - 2025)

Historic EBITDA for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to -$10.7 million.

  • vTv Therapeutics' EBITDA fell 6444.82% to -$10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.8 million, marking a year-over-year decrease of 2425.51%. This contributed to the annual value of -$24.2 million for FY2024, which is 518.39% up from last year.
  • vTv Therapeutics' EBITDA amounted to -$10.7 million in Q3 2025, which was down 6444.82% from -$7.7 million recorded in Q2 2025.
  • vTv Therapeutics' EBITDA's 5-year high stood at -$1.6 million during Q3 2021, with a 5-year trough of -$11.1 million in Q4 2021.
  • Its 5-year average for EBITDA is -$6.3 million, with a median of -$6.3 million in 2022.
  • Examining YoY changes over the last 5 years, vTv Therapeutics' EBITDA showed a top increase of 4339.69% in 2021 and a maximum decrease of 70704.92% in 2021.
  • Quarter analysis of 5 years shows vTv Therapeutics' EBITDA stood at -$11.1 million in 2021, then skyrocketed by 42.9% to -$6.3 million in 2022, then increased by 25.79% to -$4.7 million in 2023, then dropped by 3.93% to -$4.9 million in 2024, then crashed by 118.7% to -$10.7 million in 2025.
  • Its last three reported values are -$10.7 million in Q3 2025, -$7.7 million for Q2 2025, and -$6.5 million during Q1 2025.